Previous studies have proved that WT1 could ameliorate podocyte injury thus reducing urinary protein and serum creatinine and increasing GFR [33] via repression of the EZH2/β-catenin pathway in DN [34]. The gene discussed is EZH2; the disease is liver dysplastic nodule.